Charity Spotlight: Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK) was founded in 1884 as the nation’s first hospital devoted exclusively to cancer. Today, it is one of the world’s preeminent centers for cancer research, education, and treatment, and is recognized by the National Cancer Institute as one of only 69 NCI-designated Comprehensive Cancer Centers.
The Center’s physicians and scientists treat over 400 subtypes of cancer and have established standards of care and treatment protocols for each type and stage of the disease. Multi-disciplinary teams treat each patient, bringing together as many different specialists as needed for a particular type of disease, including surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, psychiatrists, and nurses. Surgeons at Memorial Sloan Kettering perform more cancer operations each year than anywhere else. Additionally, the Center provides a whole complement of supportive care services and resources for survivors.
With 473 beds in service, the Center admits more than 22,000 patients each year at Memorial Hospital and accommodates over 620,000 outpatient visits annually at its Manhattan and regional sites. Overall, MSK’s more than 16,000 employees include 1,029 Memorial Hospital attending staff; 766 Sloan Kettering Institute (SKI) researchers, including 93 heads of labs; and 2,195 registered nurses. The Center also trains more than 1,700 residents and clinical fellows.
The melding of research with patient care is at the heart of the Center’s lifesaving mission, and state-of-the-art research at SKI, the research arm of MSK, flourishes side-by-side with clinical investigation and treatment at Memorial Hospital. Close collaboration between the Center’s physicians and scientists is a unique strength, enabling the Center to provide the best care available today while working to discover more effective strategies to prevent, control, and ultimately cure cancer. At any given time, MSK is participating in more than 900 clinical trials.
MSK’s path-breaking collaborative programs and research centers include the Center for Molecular Oncology, which carries out genomic sequencing of tumors and advances precision medicine; Human Oncology and Pathogenesis Program, which translates new discoveries from molecular biology into clinical trials of drugs that can help patients; the Center for Cell Engineering, established to foster research on cellular therapies; the Metastasis and Tumor Ecosystems Center, which focuses on the causes, mechanisms, and treatments of the process by which cancer spreads; the Experimental Therapeutics Center, organized to advance new therapies from the laboratory to the clinical setting; the Brain Tumor Center; the Center for Comparative Medicine and Pathology; and the Center for Stem Cell Biology.
Investigators at Memorial Sloan Kettering currently are conducting hundreds of clinical trials. Additional research initiatives range from translational research, which bridges discoveries made in the laboratory and those made in the clinic; mathematical and computational research focused on analyzing and interpreting biomedical data; and new drug development.